Announce snapshot data for the IGNYTE clinical trial cohort
Delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 3 Aug 2023
- Due
- 31 Dec 2023
- Delivered
- December 2023
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Data snapshot for all 141 patients in the IGNYTE clinical trial cohort of RP1 in anti-PD1 failed melanoma expected Q4 2023”
What we found
Evidence strength A What the grades mean
The company reported data for the IGNYTE clinical trial cohort in December 2023, fulfilling the commitment to provide a data snapshot by the end of Q4 2023.
-
A Replimune Group, Inc. 8-K filed 2024-02-08
“The Company presented initial data from the full population enrolled into the registration directed anti-PD1 failed melanoma cohort from the IGNYTE clinical trial in December 2023.” ✓ confirmed on the page
-
A Replimune Group, Inc. 8-K filed 2024-02-08
“Positive data update in December 2023 for all 140 patients in the IGNYTE clinical trial cohort of RP1 in anti-PD1 failed melanoma” ✓ confirmed on the page
Market reaction: the shares moved +6.6% against the S&P 500 over the three sessions around the disclosure (7 Feb 2024 to 12 Feb 2024). What this measures
Checked 1 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical readout
- Indicative materiality
- Medium rules
- Action
- Announce
- Deliverable
- IGNYTE clinical trial data snapshot
- Target
- 141 patients
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- High
- Specificity
- High
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Replimune Group, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2023-REPL-002715 · Corrections policy